BLFS

BioLife Solutions Inc

BLFS.US biolifesolutions.com
34.89
-0.49 (-1.39%)
USD · NASDAQ
52-week range
17.86
38.10
Trading at 84% of the 52-week range
Market Cap
1.73B
P/E Ratio
35.38
Forward P/E
114.94
Book Value
8.59
Div. Yield
N/A
% Institutions
106.36%
% Insiders
2.62%

1 Year

+34.9%

3 Year

+157.1%

10 Year

+1,865.6%
Description

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Company Information

Company Name
BioLife Solutions Inc
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NASDAQ
ISIN: US09062W2044
CIK: 0000834365
CUSIP: 229049101
Currency: USD
Full Time Employees: 155
Phone: 425 402 1400
Fiscal Year End: December
IPO Date: Nov 22, 1989
Description:

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Address:

3303 Monte Villa Parkway, Bothell, WA, United States, 98021

People

Directors & Officers

Name Title Year Born
Mr. Roderick de Greef CEO & Chairman 1960
Mr. Sean Werner Ph.D. Chief Technology Officer 1974
Dr. Aby J. Mathew Ph.D. Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer 1972
Mr. Todd Berard Chief Commercial Officer 1969

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 09, 2026 Karen A Foster N/A Sale 500.00 $20.00 $10.00K
Mar 05, 2026 Karen A Foster N/A Sale 96.92K $20.15 $1.95M
Mar 03, 2026 Aby J Mathew N/A Sale 529.00 $20.74 $10.97K
Mar 03, 2026 Karen A Foster N/A Sale 418.00 $20.74 $8.67K
Mar 03, 2026 Sarah Aebersold N/A Sale 219.00 $20.74 $4.54K
Mar 03, 2026 Sean Werner N/A Sale 111.00 $20.74 $2.30K
Mar 03, 2026 Todd Berard N/A Sale 353.00 $20.74 $7.32K
Mar 03, 2026 Troy Wichterman N/A Sale 588.00 $20.74 $12.20K
Jan 06, 2026 Sarah Aebersold N/A Sale 241.00 $25.59 $6.17K
Jan 06, 2026 Troy Wichterman N/A Sale 990.00 $25.59 $25.33K
Jan 06, 2026 Todd Berard N/A Sale 344.00 $25.59 $8.80K
Jan 06, 2026 Karen A Foster N/A Sale 335.00 $25.59 $8.57K
Jan 06, 2026 Aby J Mathew N/A Sale 405.00 $25.59 $10.36K
Dec 15, 2025 Amy Duross N/A Sale 2.00K $24.60 $49.20K
Dec 15, 2025 Sarah Aebersold N/A Sale 713.00 $24.46 $17.44K
Dec 09, 2025 Aby J Mathew N/A Sale 631.00 $25.13 $15.86K
Dec 09, 2025 Karen A Foster N/A Sale 519.00 $25.13 $13.04K
Dec 09, 2025 Sarah Aebersold N/A Sale 233.00 $25.13 $5.86K
Dec 09, 2025 Todd Berard N/A Sale 358.00 $25.13 $9.00K
Dec 09, 2025 Troy Wichterman N/A Sale 1.03K $25.13 $25.96K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
T. Rowe Price Investment Management,Inc. 6.51M Mar 31, 2026 13.30% $0.09 19.21%
BlackRock Inc 6.10M Mar 31, 2026 12.48% $0.00 3.22%
Casdin Capital, LLC 4.66M Jun 30, 2026 9.52% $6.58 -21.86%
Amvescap Plc. 2.35M Mar 31, 2026 4.80% $0.00 -40.27%
Vanguard Capital Management, LLC 1.92M Mar 31, 2026 3.92% $0.00 0.00%
State Street Corp 1.58M Mar 31, 2026 3.22% $0.00 4.75%
FMR Inc 1.47M Mar 31, 2026 3.01% $0.00 -5.03%
Massachusetts Financial Services Company 1.20M Mar 31, 2026 2.45% $0.01 19.23%
Fred Alger Management, LLC 1.08M Mar 31, 2026 2.21% $0.09 -0.36%
Dimensional Fund Advisors, Inc. 1.05M Jun 30, 2026 2.14% $0.01 1.01%
Geode Capital Management, LLC 971.93K Mar 31, 2026 1.99% $0.00 1.97%
Bank of America Corp 904.10K Mar 31, 2026 1.85% $0.00 73.42%
Ameriprise Financial Inc 901.14K Mar 31, 2026 1.84% $0.00 -0.35%
Royal Bank of Canada 885.30K Mar 31, 2026 1.81% $0.00 8.06%
Vanguard Portfolio Management, LLC 865.04K Mar 31, 2026 1.77% $0.00 0.00%
Palisade Capital Management LLc 758.66K Mar 31, 2026 1.55% $0.48 -6.46%
Rockefeller Capital Management L.P. 741.35K Mar 31, 2026 1.52% $0.03 5.03%
Granahan Investment Management Inc.. 722.06K Mar 31, 2026 1.48% $0.67 49.69%
Stephens Inv Mgmt Group LLC 708.67K Jun 30, 2026 1.45% $0.21 5.28%
Cramer Rosenthal McGlynn LLC 632.81K Mar 31, 2026 1.29% $0.89 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 T. Rowe Price US Small-Cap Core Equity 2.50M 5.10% ▼ 2.62% Jun 30, 2026
2 T. Rowe Price Small-Cap Stock 2.46M 5.03% ▼ 1.38% Jul 31, 2026
3 iShares Core S&P Small-Cap ETF 2.41M 4.93% ▲ 0.03% Aug 31, 2026
4 Vanguard MStar Total Stk Mkt Idx Invest 1.46M 2.99% ▲ 0.00% Jul 31, 2026
5 T. Rowe Price Instl Small-Cap Stock 1.33M 2.71% ▼ 2.50% Jul 31, 2026
6 T. Rowe Price U.S. SC Core Eq Tr-D 1.19M 2.43% ▼ 2.48% Jun 30, 2026
7 iShares Russell 2000 ETF 1.08M 2.21% ▼ 0.57% Aug 31, 2026
8 Alger Small Cap Focus I 1.02M 2.09% ▲ 0.00% Jun 30, 2026
9 Alger Small Cap Focus Composite 1.02M 2.09% ▲ 0.00% Jun 30, 2026
10 Invesco Main Street Small Cap R6 783.89K 1.60% ▲ 0.00% Jul 31, 2026

Financial Highlights

Market Cap: $1.73B
EBITDA: $6.90M
P/E Ratio: $35.38
PEG Ratio: $65.38
Book Value: $8.59
Earnings/Share: $1.00
Profit Margin: 54.35%
Operating Margin: 5.96%
ROA (TTM): 0.26%
ROE (TTM): 12.83%
Revenue (TTM): $106.69M
Revenue/Share (TTM): $2.21
Earnings Growth (YOY): -13.90%
Revenue Growth (YOY): 21.50%

Valuation Metrics

Enterprise Value: $1.66B
Trailing P/E: 35.38
Forward P/E: 114.94

Shares Statistics

Shares Outstanding: 48.92M
Shares Float: 42.83M
% Insiders: 2.62%
% Institutions: 106.36%
Short % Float: 12.85%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$96.21M
Cost of Goods Sold
adjust
$-34.10M
Gross Profit
subtotal
$62.12M
SG&A
adjust
$-45.52M
R&D
adjust
$-7.57M
Other Operating Expense
adjust
$-9.85M
Operating Income
subtotal
$-1.08M
Other / Non-Operating Items
adjust
$-11.05M
Net Income
subtotal
$-12.13M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BLFS.US!